首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Interaction of Rifalazil with Oxidant-Generating Systems of Human Polymorphonuclear Neutrophils
【2h】

Interaction of Rifalazil with Oxidant-Generating Systems of Human Polymorphonuclear Neutrophils

机译:利福拉齐与人多形核中性粒细胞的氧化剂产生系统的相互作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

It is well acknowledged that ansamycins display immunosuppressive and anti-inflammatory properties in vitro and in vivo. Rifalazil, a new ansamycin derivative, has not been studied in the context of inflammation. In particular, there are no data on the possible interference of rifalazil with oxidant production by phagocytes. We have compared the antioxidant properties of rifalazil to those of rifampin, a drug well known in this context, by using cellular and acellular oxidant-generating systems. Oxidant production by polymorphonuclear neutrophils was measured in terms of cytochrome c reduction, lucigenin-amplified chemiluminescence (Lu-ACL), and the 2′,7′-dichlorofluorescin diacetate H2 (DCFDA-H2) technique (intracellular oxidant production). Rifalazil impaired O2 production in a concentration-dependent manner, with 50% inhibitory concentrations (IC50) (concentrations which inhibit 50% of the response) of 5.4 (30 and 60 min of incubation) and 6.4 (30 min) mg/liter, respectively, for phorbol myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine (fMLP) stimulation. In agreement with the published fMLP-like activity of rifampin, the inhibitory effect of rifampin was significantly greater for fMLP (IC50 of 5.6 mg/liter) than for PMA (IC50 of 58 mg/liter) stimulation. Alteration of intracellular oxidant production was also observed with IC50 values similar to those obtained by the cytochrome assay. In addition, rifalazil and rifampin (≥25 mg/liter) scavenged O2, as demonstrated by the acellular (hypoxanthine-xanthine oxidase) system. Interference with light detection systems was evidenced for both drugs by Lu-ACL. The clinical relevance of the antioxidant effect of rifalazil demonstrated in vitro, in particular its potential anti-inflammatory activity, requires further investigation.
机译:众所周知,安沙霉素在体外和体内均显示出免疫抑制和抗炎特性。利福拉齐是一种新的安沙霉素衍生物,尚未在炎症方面进行研究。特别是,没有关于利福拉齐对吞噬细胞产生氧化剂的可能干扰的数据。我们已经通过使用细胞和非细胞氧化剂生成系统,将利福拉齐的抗氧化性能与利福平(在这种情况下众所周知的药物)的抗氧化性能进行了比较。通过细胞色素C还原,光泽蛋白放大化学发光(Lu-ACL)和2',7'-二氯荧光素二乙酸盐H2(DCFDA-H2)技术(细胞内氧化剂产生)测量了多形核中性粒细胞产生的氧化剂。利福拉齐以浓度依赖的方式损害O2 -的产生,其50%抑制浓度(IC50)(抑制50%反应的浓度)分别为5.4(孵育30和60分钟)和6.4( 30分钟)毫克/升,分别用于佛波醇肉豆蔻酸酯乙酸盐(PMA)和甲酰基-甲硫酰基-亮氨酰-苯丙氨酸(fMLP)刺激。与已公布的利福平类似fMLP的活性相一致,利福平对fMLP(IC50为5.6 mg / L)的抑制作用要明显大于对PMA(IC50为58 mg / L)的刺激作用。还观察到细胞内氧化剂产生的改变,其IC 50值类似于通过细胞色素测定获得的IC 50值。此外,无细胞(次黄嘌呤-黄嘌呤氧化酶)系统证明,利福拉齐和利福平(≥25mg /升)清除了O2 -。 Lu-ACL证明这两种药物都干扰了光检测系统。在体外证明利福拉齐抗氧化作用的临床意义,特别是其潜在的抗炎活性,需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号